{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:31:17Z","timestamp":1786995077731,"version":"build-2736575974"},"reference-count":161,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.numecd.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:27:33Z","timestamp":1715048853000},"page":"1819-1836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-7853","authenticated-orcid":false,"given":"Patrizia","family":"Tarugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-9174","authenticated-orcid":false,"given":"Sebastiano","family":"Calandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0883","authenticated-orcid":false,"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-5361","authenticated-orcid":false,"given":"Manuela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo B.","family":"Cefal\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4667","authenticated-orcid":false,"given":"Laura","family":"D'Erasmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-383X","authenticated-orcid":false,"given":"Giuliana","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Perrone-Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-9173","authenticated-orcid":false,"given":"Patrizia","family":"Suppressa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-9209","authenticated-orcid":false,"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2024.05.002_bib1","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.numecd.2024.05.002_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.numecd.2024.05.002_bib3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.05.002_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","article-title":"Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy","volume":"227","author":"Bertolini","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2020.08.027","article-title":"Homozygous familial hypercholesterolemia in Italy: clinical and molecular features","volume":"312","author":"Bertolini","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000664","article-title":"Autosomal recessive hypercholesterolemia: update for 2020","volume":"31","author":"D'Erasmo","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.atherosclerosis.2017.05.002","article-title":"Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia","volume":"262","author":"Buonuomo","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.5551\/jat.RV17052","article-title":"Diagnosis and management of sitosterolemia","volume":"28","author":"Tada","year":"2021","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2024.05.002_bib10","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3390\/ijms22052641","article-title":"Sitosterolemia: Twenty years of discovery of the function of ABCG5 ABCG8","volume":"22","author":"Williams","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2024.05.002_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2017.08.021","article-title":"Molecular and clinical characterization of a series of patients with childhood-onset lysosomal acid lipase deficiency. Retrospective investigations, follow-up and detection of two novel LIPA pathogenic variants","volume":"265","author":"Pisciotta","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib13","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/ijms23105792","article-title":"APOE molecular spectrum in a French cohort with primary dyslipidemia","volume":"23","author":"Abou Khalil","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2024.05.002_bib14","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.05.002_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11886-019-1130-z","article-title":"Polygenic hypercholesterolemia and cardiovascular disease risk","volume":"21","author":"Sharifi","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11883-022-01018-6","article-title":"Monogenic versus polygenic forms of hypercholesterolemia and cardiovascular risk: are there any differences?","volume":"24","author":"Jacob","year":"2022","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2021.08.009","article-title":"Lipoprotein(a) in hereditary hypercholesterolemia: influence of the genetic cause, defective gene and type of mutation","volume":"349","author":"Marco-Benedi","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11883-022-01002-0","article-title":"Lipoprotein(a) as part of the diagnosis of clinical familial hypercholesterolemia","volume":"24","author":"Langsted","year":"2022","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib20","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1161\/ATVBAHA.121.316862","article-title":"What is the prevalence of familial hypercholesterolemia?","volume":"41","author":"Brunham","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.05.002_bib21","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2024.05.002_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.05.002_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2024.05.002_bib25","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2017.07.004","article-title":"Detection of familial hypercholesterolemia in patients from a general practice database","volume":"29","author":"Casula","year":"2017","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.numecd.2024.05.002_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijcard.2016.08.269","article-title":"What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database","volume":"223","author":"Guglielmi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.numecd.2021.12.024","article-title":"Search for familial hypercholesterolemia patients in an Italian community: a real-life retrospective study","volume":"32","author":"Fasano","year":"2022","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2024.05.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.07.007","article-title":"Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice","volume":"252","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.07.007","article-title":"Prevalence of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: the POSTER study","volume":"308","author":"Gulizia","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/clc.23031","article-title":"Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease","volume":"41","author":"De Luca","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child-parent familial hypercholesterolemia screening in primary care","volume":"375","author":"Wald","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacl.2017.12.009","article-title":"Prevalence of high cholesterol levels suggestive of familial hypercholesterolemia in Brazilian adolescents: data from the study of cardiovascular risk in adolescents","volume":"12","author":"Kaestner","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.atherosclerosis.2006.11.015","article-title":"Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening","volume":"196","author":"Campagna","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/jcm9010219","article-title":"A real-world experience of clinical, biochemical and genetic assessment of patients with homozygous familial hypercholesterolemia","volume":"9","author":"Di Taranto","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.atherosclerosis.2005.11.016","article-title":"Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison","volume":"188","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(02)07955-2","article-title":"Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis","volume":"359","author":"Arca","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.05.002_bib38","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","article-title":"Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia","volume":"74","author":"Trinder","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.574474","article-title":"Genetics of familial hypercholesterolemia: new insights","volume":"11","author":"Vrablik","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.numecd.2024.05.002_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2017.07.003","article-title":"The study of familial hypercholesterolemia in Italy: a narrative review","volume":"29","author":"Bertolini","year":"2017","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.numecd.2024.05.002_bib41","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/01.ATV.20.9.e41","article-title":"Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype","volume":"20","author":"Bertolini","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.05.002_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/humu.1122","article-title":"LDL receptor cDNA sequence analysis in familial hypercholesterolemia patients: 5 novel mutations with high prevalence in families originating from southern Italy","volume":"17","author":"Liguori","year":"2001","journal-title":"Hum Mutat"},{"key":"10.1016\/j.numecd.2024.05.002_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.06.011","article-title":"SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia","volume":"306","author":"Gallo","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/jpm12010071","article-title":"The role of cumulative LDL cholesterol in cardiovascular disease development in patients with familial hypercholesterolemia","volume":"12","author":"Korneva","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOL.0000000000000714","article-title":"Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods","volume":"31","author":"Ibrahim","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2022.06.1011","article-title":"Familial hypercholesterolemia: a systematic review of modeling studies on screening interventions","volume":"355","author":"Jahn","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib47","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacl.2017.01.002","article-title":"Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia","volume":"11","author":"L\u00e1zaro","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib48","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjco.2019.05.001","article-title":"Awareness of familial hypercholesterolemia among healthcare providers involved in the management of acute coronary syndrome in victoria, Australia","volume":"1","author":"Mirzaee","year":"2019","journal-title":"CJC Open"},{"key":"10.1016\/j.numecd.2024.05.002_bib50","doi-asserted-by":"crossref","first-page":"634","DOI":"10.31128\/AJGP-04-21-5952","article-title":"Awareness of familial hypercholesterolaemia in Australian primary care: a qualitative descriptive study","volume":"50","author":"Bulsara","year":"2021","journal-title":"Aust. J. Gen. Pract"},{"key":"10.1016\/j.numecd.2024.05.002_bib51","article-title":"A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia","author":"Meng","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.atherosclerosis.2018.06.858","article-title":"Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review","volume":"277","author":"Groselj","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOL.0000000000000163","article-title":"Targeted next-generation sequencing in monogenic dyslipidemias","volume":"26","author":"Hegele","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib54","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.cjca.2018.07.479","article-title":"Whole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia","volume":"34","author":"Iacocca","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib55","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-018-05747-8","article-title":"Deep-coverage whole genome sequences and blood lipids among 16,324 individuals","volume":"9","author":"Natarajan","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.numecd.2024.05.002_bib56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/gim.2017.151","article-title":"Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis","volume":"20","author":"Chora","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.gim.2021.09.012","article-title":"The clinical genome resource (ClinGen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification","volume":"24","author":"Chora","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib58","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2019.103831","article-title":"Familial hypercholesterolemia: a complex genetic disease with variable phenotypes","volume":"63","author":"Di Taranto","year":"2020","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.numecd.2024.05.002_bib60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cge.14036","article-title":"Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: implications for diagnosis improvement","volume":"100","author":"Di Taranto","year":"2021","journal-title":"Clin Genet"},{"key":"10.1016\/j.numecd.2024.05.002_bib61","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1515\/cclm-2018-1037","article-title":"Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL\/HDL ratio","volume":"57","author":"Di Taranto","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib62","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2021.01.008","article-title":"Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries","volume":"319","author":"Futema","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib64","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1253\/circj.CJ-19-0317","article-title":"Rare and deleterious mutations in ABCG5\/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype","volume":"83","author":"Tada","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2024.05.002_bib65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.atherosclerosis.2018.06.819","article-title":"Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia","volume":"277","author":"Alves","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib66","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib67","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2024.05.002_bib68","article-title":"Human genetics program. Familial hypercholesterolemia FH): report of a second WHO consultation","year":"1999","journal-title":"Geneva"},{"key":"10.1016\/j.numecd.2024.05.002_bib69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2019.06.905","article-title":"Expert group from the Spanish Arteriosclerosis Society. Toward a new clinical classification of patients with familial hypercholesterolemia: one perspective from Spain","volume":"287","author":"Masana","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib70","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/2047487317702040","article-title":"Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia","volume":"24","author":"Rubba","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.numecd.2024.05.002_bib71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MOL.0000000000000813","article-title":"Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia","volume":"33","author":"Antoniazi","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib72","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/nu14071344","article-title":"Mediterranean dietary treatment in hyperlipidemic children: should it Be an option?","volume":"14","author":"Massini","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.numecd.2024.05.002_bib73","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib74","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new\u00a0treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib75","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib76","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1210\/jc.2013-3274","article-title":"Sitosterolemia presenting with severe hypercholesterolemia and intertriginous xanthomas in a breastfed infant: case report and brief review","volume":"99","author":"Park","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2024.05.002_bib77","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib78","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.05.002_bib79","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/eurheartj\/eht350","article-title":"Stress echo applications beyond coronary artery disease","volume":"35","author":"Picano","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11883-020-00881-5","article-title":"Women living with familial hypercholesterolemia: challenges and considerations surrounding their care","volume":"22","author":"Balla","year":"2020","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib81","first-page":"3","article-title":"The risk of cardiovascular disease with second- and third-generation oral contraceptives","volume":"7","author":"Kovacs","year":"2002","journal-title":"Medscape Women Health"},{"key":"10.1016\/j.numecd.2024.05.002_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"issue":"3 Suppl","key":"10.1016\/j.numecd.2024.05.002_bib83","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib84","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2018.05.038","article-title":"Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies","volume":"277","author":"Botha","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib85","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosissup.2015.02.024","article-title":"Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis","volume":"18","author":"Blaha","year":"2015","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.numecd.2024.05.002_bib86","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of familial hypercholesterolemia in pregnancy","volume":"32","author":"Graham","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib87","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11886-018-1014-7","article-title":"Lipid screening, action, and follow-up in children and adolescents","volume":"20","author":"Wiegman","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib89","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pathol.2018.10.015","article-title":"Improving the detection of familial hypercholesterolaemia","volume":"51","author":"Lan","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.numecd.2024.05.002_bib90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-021-00926-3","article-title":"Current approach to the diagnosis and treatment of heterozygote and homozygous FH children and adolescents","volume":"23","author":"Cohen","year":"2021","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib91","series-title":"GeneReviews ((R))","article-title":"Familial hypercholesterolemia","author":"Ison","year":"1993"},{"key":"10.1016\/j.numecd.2024.05.002_bib92","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF01247350","article-title":"Chorionic DNA analysis for the prenatal diagnosis of familial hypercholesterolaemia","volume":"92","author":"Coviello","year":"1993","journal-title":"Hum Genet"},{"key":"10.1016\/j.numecd.2024.05.002_bib93","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/heartjnl-2015-308845","article-title":"Cardiovascular risk stratification in familial hypercholesterolaemia","volume":"102","author":"Sharifi","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2024.05.002_bib94","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacl.2011.05.002","article-title":"Fatal cardiac atherosclerosis in a child 10 years after liver transplantation: a case report and a review","volume":"5","author":"El-Rassi","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib95","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tcm.2020.03.004","article-title":"Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels","volume":"31","author":"Bianconi","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib96","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/eurheartj\/ehq235","volume":"32","author":"Perrone-Filardi","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib97","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.05.002_bib98","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/VHRM.S13496","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","author":"Hamilton-Craig","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.numecd.2024.05.002_bib99","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.05.002_bib100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib101","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib102","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib103","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.1965.03080170017004","article-title":"Cholestyramine resin therapy for hypercholesteremia: clinical and metabolic studies","volume":"192","author":"Hashim","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.05.002_bib104","series-title":"StatPearls. Treasure island (FL)","article-title":"Antilipemic agent bile acid sequestrants","author":"Lent-Schochet","year":"2023"},{"key":"10.1016\/j.numecd.2024.05.002_bib105","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib106","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13219","article-title":"Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study","volume":"290","author":"Casula","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib107","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.05.002_bib108","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.numecd.2024.05.002_bib109","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2024.05.002_bib110","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.05.002_bib111","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.amjmed.2020.03.056","article-title":"A meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy","volume":"133","author":"Alder","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.RV17029","article-title":"Liver transplantation for homozygous familial hypercholesterolemia","volume":"26","author":"Ishigaki","year":"2019","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2024.05.002_bib113","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2016.05.042","article-title":"Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia","volume":"118","author":"Martinez","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2024.05.002_bib116","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","author":"Collaboration EASFHS","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.05.002_bib117","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacl.2021.11.014","article-title":"Health-related quality of life in homozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"16","author":"Alothman","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib118","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00467-022-05541-1","article-title":"An update on lipid apheresis for familial hypercholesterolemia","volume":"38","author":"Taylan","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.numecd.2024.05.002_bib119","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","article-title":"Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9\u00a0and ANGPTL3 inhibitors","volume":"23","author":"Pirillo","year":"2021","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2024.05.002_bib120","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (Low-Density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.05.002_bib121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.05.002_bib122","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib123","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.05.002_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: a review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.numecd.2024.05.002_bib125","year":"2013"},{"key":"10.1016\/j.numecd.2024.05.002_bib126","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.numecd.2024.05.002_bib127","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","article-title":"Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey","volume":"16","author":"D'Erasmo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.numecd.2024.05.002_bib129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2459\/JCM.0000000000000620","article-title":"Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience","volume":"19","author":"Sperlongano","year":"2018","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.numecd.2024.05.002_bib130","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D'Erasmo","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.numecd.2024.05.002_bib131","series-title":"Nota Informativa Importante su Lojuxta (lomitapide)","year":"2021"},{"key":"10.1016\/j.numecd.2024.05.002_bib132","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2017.06.013","article-title":"Clinical and biochemical characteristics of individuals with low cholesterol syndromes: a comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia","volume":"11","author":"Di Costanzo","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib133","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/ijms22020742","article-title":"The interplay between angiopoietin-like proteins and adipose tissue: another piece of the relationship between adiposopathy and cardiometabolic diseases?","volume":"22","author":"Bini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2024.05.002_bib134","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOL.0000000000000668","article-title":"Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency","volume":"31","author":"Arca","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib136","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the treatment of homozygous familial hypercholesterolemia","volume":"29","author":"Bajaj","year":"2022","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2024.05.002_bib137","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib138","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2024.05.002_bib139","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.numecd.2024.05.002_bib140","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib141","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.05.002_bib142","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2024.05.002_bib143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/14779072.1.1.11","article-title":"Ezetimibe: a novel option for lowering cholesterol","volume":"1","author":"Davidson","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.numecd.2024.05.002_bib144","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hfc.2021.07.008","article-title":"New frontiers in the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Cesaro","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.numecd.2024.05.002_bib145","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14656566.2017.1340941","article-title":"Lomitapide for the treatment of hypercholesterolemia","volume":"18","author":"Berberich","year":"2017","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.numecd.2024.05.002_bib146","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib147","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.05.002_bib148","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5551\/jat.45708","article-title":"Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study","volume":"26","author":"Nohara","year":"2019","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2024.05.002_bib149","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.05.002_bib150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2047487319870007","article-title":"Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia","volume":"27","author":"Kolovou","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.numecd.2024.05.002_bib151","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib152","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.05.002_bib153","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.05.002_bib154","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.05.002_bib155","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.05.002_bib156","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.05.002_bib157","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.05.002_bib158","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacl.2017.11.005","article-title":"The UK paediatric familial hypercholesterolaemia register: statin-related safety and 1-year growth data","volume":"12","author":"Humphries","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.05.002_bib159","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1537-2995.2009.02135.x","article-title":"Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis","volume":"49","author":"Stefanutti","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.numecd.2024.05.002_bib160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"Supplement 1","key":"10.1016\/j.numecd.2024.05.002_bib161","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.atherosclerosis.2023.06.945","article-title":"Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - results from the efficacy phase of the APH-19 study","volume":"379","author":"Masana","year":"2023","journal-title":"Atherosclerosis"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324001704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324001704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T02:52:50Z","timestamp":1721962370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475324001704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":161,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0939475324001704"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.05.002","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}